Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia

Molecular detection of minimal residual disease (MRD) has become established to assess remission status and guide therapy in patients with ProMyelocytic Leukemia-RARA+ acute promyelocytic leukemia (APL). However, there are few data on tracking disease response in patients with rarer retinoid resista...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Frontiers in oncology 2011, Vol.1, p.35-35
Hauptverfasser:	Jovanovic, Jelena V, Rennie, Kristian, Culligan, Dominic, Peniket, Andrew, Lennard, Anne, Harrison, Justin, Vyas, Paresh, Grimwade, David
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Myeloid Leukemia Minimal Residual Disease Oncology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Molecular detection of minimal residual disease (MRD) has become established to assess remission status and guide therapy in patients with ProMyelocytic Leukemia-RARA+ acute promyelocytic leukemia (APL). However, there are few data on tracking disease response in patients with rarer retinoid resistant subtypes of APL, characterized by PLZF-RARA and STAT5b-RARA. Despite their rarity (
ISSN:	2234-943X 2234-943X
DOI:	10.3389/fonc.2011.00035